公开(公告)号：US08962666B2

公开(公告)日：2015-02-24

申请号：US13677071

申请日：2012-11-14

Applicant: Maastricht University ,  Academic Hospital Maastricht

Inventor： Peter Joseph Emans ,  Lodewijk Willem Van Rhijn ,  Tim Johannes Maria Welting ,  Mike De Leeuw

IPC: A61K31/42 ,  A61K31/40 ,  A61K9/00 ,  A61K31/728 ,  A61L27/52 ,  A61L27/54 ,  A61K38/20

CPC classification number: A61K9/0019 ,  A61K9/0024 ,  A61K31/42 ,  A61K31/728 ,  A61K38/2013 ,  A61L27/52 ,  A61L27/54 ,  A61L2300/252 ,  A61L2300/414 ,  A61L2300/426 ,  A61L2300/432 ,  A61L2300/452

Abstract: The invention is in the field of methods for medical treatment. It provides an improved method for repairing damaged cartilage and/or preventing cartilage degeneration in tissue, in particular in a joint by administering a pharmaceutically active agent directly into the fat pad of a joint. The pharmaceutically active agent is preferably selected from the group consisting of agents that stimulate chondrogenic differentiation and/or cartilage matrix synthesis; agents that inhibit osteogenesis and/or hypertrophy, anti-inflammatory agents, agents that inhibit apoptosis of chondrocytes, agents that inhibit senescence of chondrocytes and agents that enhance lubrication of a joint.

Abstract translation: 本发明在医疗方法领域。 它提供了通过将药物活性剂直接施用到关节的脂肪垫中来修复损伤的软骨和/或预防组织中软骨退化的改进方法，特别是在关节中。 药物活性剂优选选自刺激软骨形成分化和/或软骨基质合成的试剂; 抑制成骨和/或肥大的药剂，抗炎剂，抑制软骨细胞凋亡的药剂，抑制软骨细胞衰老的药剂和增强关节润滑的药剂。

公开(公告)号：US11649502B2

公开(公告)日：2023-05-16

申请号：US17025345

申请日：2020-09-18

Applicant: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN ,  MAASTRICHT UNIVERSITY

Inventor： Alexander Pfeifer ,  Joschka Buyel ,  Yong Chen ,  Wouter Van Marken Lichtenbelt

IPC: C12Q1/68 ,  C12Q1/6883 ,  C12Q1/6806 ,  C12Q1/686 ,  A61K31/36

CPC classification number: C12Q1/6883 ,  C12Q1/6806 ,  C12Q1/686 ,  A61K31/36 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/178

Abstract: The present invention relates to methods for detecting activation of a brown/beige fat cell or brown/beige adipose tissue (BAT) in a biological sample taken from a mammal to be diagnosed, comprising measuring the amount of miR-92 in said sample. The invention furthermore relates to diagnostic and clinical applications of the methods of the invention.

公开(公告)号：US20230075965A1

公开(公告)日：2023-03-09

申请号：US17793581

申请日：2021-01-22

Applicant: Constantine S. Mitsiades ,  Michal Sheffer ,  Jennifer Roth ,  Chris C. Mader ,  Channing Yu ,  Todd R. Golub ,  Lotte Wieten ,  Dana-Farber Cancer Institute, Inc. ,  The Broad Institute, Inc. ,  Maastricht University Medical Center

Inventor： Constantine S. Mitsiades ,  Michal Sheffer ,  Jennifer Roth ,  Chris C. Mader ,  Channing Yu ,  Todd R. Golub ,  Lotte Wieten

IPC: G01N33/574 ,  A61K35/17 ,  A61P35/00 ,  A61P37/04 ,  C12N15/10 ,  A61K31/713 ,  A61K31/4045 ,  A61K45/06

Abstract: The present invention relates, in part, to methods for selecting subjects for and treating subjects with a type of immunotherapy based on certain biomarkers from the subjects.

公开(公告)号：US20180202000A1

公开(公告)日：2018-07-19

申请号：US15752792

申请日：2016-09-27

Applicant: Rheinische Friedrich-Wilhelms-Universität Bonn ,  Maastricht University

Inventor： Alexander PFEIFER ,  Joschka BUYEL ,  Yong CHEN ,  Wouter VAN MARKEN LICHTENBELT

IPC: C12Q1/6883 ,  C12Q1/686 ,  C12Q1/6806

CPC classification number: C12Q1/6883 ,  A61K31/36 ,  C12Q1/6806 ,  C12Q1/686 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/178

Abstract: The present invention relates to methods for detecting activation of a brown/beige fat cell or brown/beige adipose tissue (BAT) in a biological sample taken from a mammal to be diagnosed, comprising measuring the amount of miR-92 in said sample. The invention further-more relates to diagnostic and clinical applications of the methods of the invention.

公开(公告)号：US20170340887A1

公开(公告)日：2017-11-30

申请号：US15610231

申请日：2017-05-31

Applicant: Medtronic, Inc. ,  Maastricht University Medical Centre

Inventor： Elien B. Engels ,  Kevin Vernooy ,  Alfonso Aranda Hernandez ,  Frits W. Prinzen ,  Jeffrey M. Gillberg

IPC: A61N1/365 ,  A61N1/372 ,  A61B5/0472 ,  A61N1/39 ,  A61B5/0468

CPC classification number: A61N1/36592 ,  A61B5/0468 ,  A61B5/0472 ,  A61N1/36521 ,  A61N1/36564 ,  A61N1/3682 ,  A61N1/3684 ,  A61N1/3686 ,  A61N1/37217 ,  A61N1/3956 ,  A61N1/3962

Abstract: In some examples, controlling delivery of CRT includes delivering ventricular pacing according to a sequence of different values of at least one of A-V delay or V-V delay, and acquiring one or more electrograms from respective vectors. For each of the different values of the at least one of A-V delay or V-V delay, at least one of a QRS amplitude or a QRS area may be determined based on the one or more electrograms, and a target change in QRS amplitude or QRS area between adjacent ones of the values of the at least one of A-V delay or V-V delay of the sequence may be identified. In response to the identification of the target change, the implantable medical device may deliver the ventricular pacing at a value of the at least one of A-V delay or V-V delay determined based on the identification to provide CRT.

公开(公告)号：US20190162737A1

公开(公告)日：2019-05-30

申请号：US16264779

申请日：2019-02-01

Applicant: Roche Diagnostics Operations, Inc. ,  Maastricht University Medical Center

Inventor： Johann Karl ,  Peter Kastner ,  Roberto Latini ,  Serge Masson ,  Ursula-Henrike Wienhues-Thelen ,  Andre Ziegler ,  Manuel Dietrich ,  Ulrich Schotten ,  Vinzent Rolny

IPC: G01N33/68

Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of ESM-1 in a sample from the subject, and comparing the amount of ESM-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure.

公开(公告)号：US20160228408A1

公开(公告)日：2016-08-11

申请号：US15019581

申请日：2016-02-09

Applicant: Ludwig-Maximilians-Universitaet Muenchen ,  Maastricht University ,  Academisch Ziekenhuis Maastricht

Inventor： Esther LUTGENS ,  Christian WEBER ,  Gerry NICOLAES

IPC: A61K31/381 ,  A61K31/341 ,  A61K31/137

CPC classification number: A61K31/381 ,  A61K31/137 ,  A61K31/341 ,  C07C251/24 ,  C07C251/26 ,  C07D307/52 ,  C07D333/22

Abstract: The present invention relates to compounds acting as selective inhibitors of CD40-TRAF6 interaction, their use as medicaments and their use in the treatment of (chronic) inflammatory diseases. The present invention also relates to pharmaceutical compositions comprising these compounds.

公开(公告)号：US20220081725A1

公开(公告)日：2022-03-17

申请号：US17418725

申请日：2019-12-16

Applicant: Fundación Para La Investigación Del Hospital Universitario La Fe De La Comunidad Valenciana ,  Maastricht University

Inventor： David Hervàs Marìn ,  Ana Santaballa Beltràn ,  Carmen Salvador Coloma ,  Rubèn Carrero Garcìa ,  Rafael Sanchez Sanchez ,  Akaitz Dorronsoro Gonzàlez ,  Imelda Ontoria Oviedo ,  Sandra Tejedor Gascòn ,  Estaban Peiró Molina ,  Amparo Hernàndiz Martinez ,  Hernán González-King ,  María Ciria Calduch ,  Delia Castellano Izquierdo ,  Joaquín Panadero Romero ,  Jose Anastasio Montero Argudo ,  Pilar Sepúlveda Sanchis ,  Nahuel A. García ,  Florian Caiment ,  Jos Kleinjans ,  Stephane Heymans ,  Jort Merken

IPC: C12Q1/6886

Abstract: The present invention refers to an in vitro method for predicting cardiotoxicity risk in a cancer patient receiving, or susceptible to receive, anthracyclines chemotherapy based on the determination of the expression levels of a combination of 10 circulating miRNAs consisting of miRNA 16-5p, miRNA 22-3p, miRNA 30b-5p/30c-5p, miRNA 92b-3p, miRNA 148a-3p, miRNA-150-5p, miRNA-192-5p, miRNA 215-5p, miRNA 486-3p/486-5p and miRNA-4732-3p, in a biological sample isolated from the patient. The present invention also refers to said set of 10 circulating miRNAs for its use as biomarker of prediction of cardiotoxicity risk in cancer patients receiving, or susceptible to receive, anthracyclines chemotherapy. Finally, a method for the prevention of cardiotoxicity, in patients receiving or susceptible to receive anthracyclines chemotherapy, that comprises modulating the expression levels of the set of said 10 circulating miRNAS is contemplated.

公开(公告)号：US09750717B2

公开(公告)日：2017-09-05

申请号：US15019581

申请日：2016-02-09

Applicant: Ludwig-Maximilians-Universitaet Muenchen ,  Maastricht University ,  Academisch Ziekenhuis Maastricht

Inventor： Esther Lutgens ,  Christian Weber ,  Gerry Nicolaes

IPC: A61K31/381 ,  C07D333/22 ,  C07C251/24 ,  C07C251/26 ,  C07D307/52 ,  A61K31/137 ,  A61K31/341

CPC classification number: A61K31/381 ,  A61K31/137 ,  A61K31/341 ,  C07C251/24 ,  C07C251/26 ,  C07D307/52 ,  C07D333/22

Abstract: The present invention relates to compounds acting as selective inhibitors of CD40-TRAF6 interaction, their use as medicaments and their use in the treatment of (chronic) inflammatory diseases. The present invention also relates to pharmaceutical compositions comprising these compounds.

公开(公告)号：US20160355489A1

公开(公告)日：2016-12-08

申请号：US15119034

申请日：2015-02-10

Applicant: UNIVERSITA DEGLI STUDI DI GENOVA ,  THE TRUSTEES OF COLUMBIA UNIVERSITY ,  MAASTRICHT UNIVERSITY

Inventor： Olga BRUNO ,  Chiara BRULLO ,  Alessia ROMUSSI ,  Ernesto FEDELE ,  Roberta RICCIARELLI ,  Ottavio ARANCIO ,  Jos PRICKAERTS

IPC: C07D261/04 ,  C07D261/08 ,  C07D207/34 ,  C07D231/12 ,  C07D401/06 ,  C07D207/337 ,  C07D413/06 ,  C07D261/18

CPC classification number: C07D261/04 ,  C07D207/337 ,  C07D207/34 ,  C07D231/12 ,  C07D261/08 ,  C07D261/18 ,  C07D401/06 ,  C07D403/06 ,  C07D413/06

Abstract: Compounds of formula (I), wherein Z=cyclopentyl. cyclopropylmethyl, —CH3; R′=—CH3, CHF2, X=formula (II) (III) (IV) (V) Y=—CO; —C═O(CH2), —CH(OH)—CH2, —CH2—C═O, —CH2—CH2—C═O; —CH2—CH(OH)—CH2, —CH2—CH(OCOR1)—CH2 NR2=—N(CH2—CH2OH)2, formula (VI) (VII) (VIII) (IX) (X) (XI) R1=optionally substituted C1-C8 alkyl, optionally substituted aryl; optionally substituted aralkyl, preferably C1-C3 alkyl, more preferably CH3; and enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof; these compounds have a PDE4D inhibiting activity and can be used as a medicament for treating dementia, in particular Alzheimer disease, and for improving memory.